This study reports the development and preclinical characterization of NI-3201, a PD-L1×CD28 bispecific antibody designed to promote T-cell activity and antitumor function through a dual mechanism of action: blocking the PD-L1/PD-1 immune checkpoint pathway and conditionally providing T-cell co-stimulation via CD28 when engaging PD-L1+ tumors or immune cells.
NI-3201 enhances T-cell effector functionality in vitro and induces tumor regression and immunologic memory in vivo. It shows synergistic T cell–dependent cytotoxicity when combined with T-cell engagers and exhibits favorable tolerability and pharmacokinetics in nonhuman primates.
Humanized PD-L1 and CD28 transgenic mouse models developed by genOway, expressing human PD-L1 and CD28 to evaluate the in vivo efficacy and safety of NI-3201.
Cancer immunotherapy, Bispecific antibodies, PD-L1 blockade, CD28 co-stimulation, T-cell activation
Humanized PD-L1 and CD28 transgenic mouse models, κλ-body platform, Immunocompetent syngeneic models, Pharmacokinetic and safety assessments
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
